Phase 1 study of elotuzumab (Elo) in combination with lenalidomide/dexamethasone (Len/dex) in Japanese patients (pts) with relapsed or refractory multiple myeloma (RRMM) and long-term follow-up

Autor:	Gen Kinoshita, Y. Asaeda, Takaaki Chou, H. Nagai, S. Lida, Eric Bleickardt
Rok vydání:	2015
Předmět:	Oncology Cancer Research medicine.medical_specialty Long term follow up business.industry Induction chemotherapy Refractory Multiple Myeloma Hematology Surgery Novel agents Internal medicine medicine Elotuzumab business Dexamethasone Lenalidomide medicine.drug
Zdroj:	Clinical Lymphoma Myeloma and Leukemia. 15:e162
ISSN:	2152-2650
DOI:	10.1016/j.clml.2015.07.376
Popis:	e162 induction chemotherapy (p>0.5) was associated to a higher rate of ER. Median OS was shorter for the ER group (19.9 months) compared to 81 months for those patients relapsing >12 months. (p1⁄40.0001) In conclusion, patients with ER after auto-SCT remain to be a challenge. Even with the advent of novel agents, patients with ER had poor outcomes. ER seems to be associated to HRC and low degree of response. Patients with these features should be considered for novel alternatives, aiming to achieve and sustain the deepest possible response. More biological insights on ER cases are needed to further improve survival outcomes. Table 1 Clinical Characteristics Characteristic N[212 Age (median) 58
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::eaa8ee74c8de64293b2890a68d2d93fa https://doi.org/10.1016/j.clml.2015.07.376 Zobrazit plný text záznamu Full Text from ScienceDirect